Paclitaxel trevatide

N/A

Report date: 2022/03/17 13:27:02

Base Information

Drug NamePaclitaxel trevatide
Drug Alias NameAngiopep peptide + paclitaxel conjugate – AngiochemAngiopep-2 paclitaxel conjugate - AngiochemSNG-1005GRN-1005ANG-1005
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionMitosis inhibitorsTubulin inhibitorsTubulin polymerisation promoters +[4] 
TargetsTubulinApoptosis regulator Bcl-2
Therapy Area/IndicationsBrain metastasesSolid tumoursNeoplasm Metastasis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAngiochem Inc
China Registration ClassN/A

Develop Information

Active CompaniesXinogen (Hong Kong) Pharma Co LtdAngiochem IncShenogen Pharma Group Ltd +[4] 
Inactive CompaniesNational Cancer Institute
Active IndicationsBrain metastasesNeoplasm MetastasisMeningeal Carcinomatosis +[4] 
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBank